Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
| Previous Close | 222.60 |
| Open | 222.00 |
| Bid | 223.00 x 0 |
| Ask | 223.30 x 0 |
| Day's Range | 221.60 - 225.80 |
| 52 Week Range | 156.00 - 245.40 |
| Volume | |
| Avg. Volume | 772,083 |
| Market Cap | 66.144B |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | 26.36 |
| EPS (TTM) | 8.50 |
| Earnings Date | Jul 19, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 247.25 |
- GlobeNewswire
Sobi Announces Launch of the INTO-HLH Registry, a Disease Registry for Patients with Hemophagocytic Lymphohistiocytosis (HLH)
INTO-HLH Registry serves as the first in-depth disease registry for the HLH medical and patient community in North AmericaWALTHAM, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Sobi® North America today announced the launch of the INTO-HLH Registry, a new disease registry for patients with hemophagocytic lymphohistiocytosis (HLH). The INTO-HLH Registry (Insight into the Natural history and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis) will enroll pediatric and adult patients with HLH, a r
- Zacks
Swedish Orphan Biovitrum (BIOVF) Stock Jumps 5.3%: Will It Continue to Soar?
Swedish Orphan Biovitrum (BIOVF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- GlobeNewswire
Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress
WALTHAM, Mass. and STOCKHOLM, Sweden, June 10, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today reported new analyses of Phase 3 studies that reinforce the robust efficacy and safety profile of EMPAVELI®/Aspaveli® (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH). The data will be presented at the hybrid European Hematology Association (EHA) Congress in Vienna, Austria. New analyses demonstrated that treatment with EMPAVELI resulted in
